GWP42003-P

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome, RTT

Trial Timeline

Feb 28, 2020 → Jun 9, 2021

NCT ID

NCT04252586

About GWP42003-P

GWP42003-P is a phase 3 stage product being developed by Jazz Pharmaceuticals for Rett Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04252586. Target conditions include Rett Syndrome, RTT.

What happened to similar drugs?

3 of 8 similar drugs in Rett Syndrome were approved

Approved (3) Terminated (2) Active (3)

✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved

✅Esomeprazole + LansoprazoleAstraZenecaApproved

✅Esomeprazole MagnesiumAstraZenecaApproved

❌GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3

❌trofinetideAcadia PharmaceuticalsPhase 3

🔄TrofinetideAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04485104	Phase 3	Terminated	May 19, 2021	Jan 28, 2025	Seizure in Participants With Tuberous Sclerosis Complex
NCT04133480	Approved	Withdrawn	Oct 1, 2020	Dec 1, 2021	Lennox-Gastaut Syndrome
NCT04252586	Phase 3	Terminated	Feb 28, 2020	Jun 9, 2021	Rett Syndrome
NCT02954887	Phase 3	Completed	May 12, 2017	Jun 13, 2019	Infantile Spasms
NCT02953548	Phase 3	Completed	Apr 24, 2017	May 7, 2018	Infantile Spasms
NCT02607904	Phase 2	Completed	Dec 15, 2016	May 27, 2019	Epilepsy
NCT02544750	Phase 3	Completed	Aug 31, 2016	Jun 11, 2021	Tuberous Sclerosis Complex

Competing Products

20 competing products in Rett Syndrome

See all competitors

Product	Company	Stage	Hype Score
Esomeprazole + Aspirin + Rofecoxib	AstraZeneca	Approved	43
Esomeprazole + Lansoprazole	AstraZeneca	Approved	43
Esomeprazole Magnesium	AstraZeneca	Approved	43
AZD5213 and placebo	AstraZeneca	Phase 2	35
fingolimod (FTY720)	Novartis	Phase 1/2	32
PF-03654746 + Placebo + Placebo + PF-03654746	Pfizer	Phase 2	27
Aripiprazole	Bristol Myers Squibb	Pre-clinical	18
NBI-98854	Neurocrine Biosciences	Phase 2	24
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	24
Valbenazine	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 1	26
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Abobotulinum toxin A	Ipsen	Pre-clinical	19
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	29
trofinetide	Acadia Pharmaceuticals	Phase 3	29
Trofinetide	Acadia Pharmaceuticals	Phase 3	37
Trofinetide	Acadia Pharmaceuticals	Phase 2/3	27